Previous 10 | Next 10 |
2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...
2024-06-13 14:03:52 ET Summary Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis. The global idiopathic pulmonary fibrosis market size is projected to reac...
2024-06-12 12:33:43 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024 PR Newswire Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA ® and Progress in Addressing Sjögren's Disease THOUSAND OAKS, Calif. , June 12, 2024...
2024-06-11 09:14:04 ET More on Viridian Therapeutics Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript Viridian Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Viridian Therapeutics Hi...
2024-06-10 11:48:01 ET Amgen Inc. (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 09:20 A.M. ET Company Participants James E. Bradner – EVP of Research and Development & Chief Scientific Officer Peter H. Griffith – EVP &a...
2024-06-10 09:00:00 ET Summary Invesco Dow Jones Industrial Average Dividend ETF holds the 28 stocks of the Dow Jones paying a dividend, weighted based on yields. DJD is better balanced across sectors than its parent index but is quite concentrated in its top holdings. DJD loo...
2024-06-09 09:44:11 ET Summary Cullinan Therapeutics, Inc. has seen a recent pullback in its shares, but they are still up 50% since mid-April after rebranding and focusing on autoimmune diseases. The company's lead asset is zipalertinib, an oral EGFR inhibitor being evaluated in ...
2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...
2024-06-07 07:05:00 ET Summary Warren Buffett once opined on how to live off of dividends in retirement. We discuss a simple way to follow his advice on this. We also share how to further enhance the yield on this portfolio while still generating strong dividend growth and kee...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...
2024-07-12 12:30:05 ET UBS analyst issues NEUTRAL recommendation for AMGN on July 12, 2024 10:22AM ET. The previous analyst recommendation was Neutral. AMGN was trading at $331.355 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...